Stockreport

Catalyst Pharmaceuticals Announces AGAMREE® Now Commercially Available in the U.S. for the Treatment of Duchenne Muscular Dystrophy (DMD) [Yahoo! Finance]

Catalyst Pharmaceuticals, Inc.  (CPRX) 
Last catalyst pharmaceuticals, inc. earnings: 3/16 05:26 pm Check Earnings Report
US:NASDAQ Investor Relations: ir.catalystpharma.com
PDF Available in the U.S. by Prescription for Patients Aged Two Years and Older Catalyst Pathways ® Program will Support AGAMREE Patients and Available to Help Ensure DMD [Read more]